Exagen (XGN)
(Delayed Data from NSDQ)
$2.02 USD
-0.02 (-0.98%)
Updated Jun 7, 2024 03:59 PM ET
After-Market: $2.02 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth C Momentum B VGM
Brokerage Reports
0 items in cart
Exagen Inc. [XGN]
Reports for Purchase
Showing records 21 - 36 ( 36 total )
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Recovery in Dx Testing with Larger Menu in 2023
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Strong Quarter, Strong Outlook, Momentum Building
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
The Best Type of ''Guide Down''; Building Visibility Warrants Higher Multiple
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Worth More with Less SIMPONI; Diagnostic Sum-of-Parts; Raising Target Price to $33
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Molecular Diagnostic Market Improves in 3Q; S-3 Filing Potentially Addresses 70% Valuation Discount
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Initiating Coverage on Life Science Technology, Bioproduction, - Diagnostics
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Initiating Coverage at Overweight; Micro-Cap Discount for Autoimmune Molecular Dx Leader
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Initiating Coverage on Life Science Technology, Bioproduction, - Diagnostics
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department